UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets hard-to-treat liposarcoma
Disease control OngoingThis study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink or slow advanced dedifferentiated liposarcoma, a rare soft tissue cancer. About 16 adults whose cancer has returned, spread, or cannot be removed by surgery will receive the treatment. The mai…
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy shows promise for rare, aggressive cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug cemiplimab to the targeted therapy palbociclib works better than palbociclib alone for people with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. About 77 adults with cancer that has spread or cannot be …
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 13, 2026 16:01 UTC